Reference number
1692-H

SPECIALTY QUANTITY LIMIT PROGRAM

DUPIXENT (dupilumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Dupixent 200 mg/ 1.14 mL pre-filled syringe	400 mg per 28 days	400 mg per 14 days	Atopic dermatitis: • Adults and adolescents weighing ≥ 60 kg: Initial dose of 600 mg (two 300 mg injections), followed by 300 mg every other week. • Adolescents weighing < 60 kg: Initial dose of 400 mg (two 400 mg injections), followed by 200 mg every other week. Asthma: • Initial dose of 400 mg (two 200 mg injections), followed by 200 mg every other week, or • Initial dose of 600 mg (two 300 mg injections), followed by 300 mg every other week • Patients with oral corticosteroid-dependent asthma, or with co-morbid moderate-to-severe atopic dermatitis for which Dupixent is indicated: initial dose of 600 mg followed by 300 mg every other week
Dupixent 300 mg/ 2 mL pre-filled syringe	600 mg per 28 days	600 mg per 14 days	

* Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCES

1. Dupixent [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; March 2019.

CVS caremark™